Cellectar Biosciences Inc. (CLRB) 3.13 $CLRB
Cellectar Bio initiates Phase 1 study of I-131-CLR1404 for Orphan Drug indication
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 12:08PM CDT
CLRB: 3.13 (+0.02)
Cellectar Biosciences Initiates Proof-of-Concept Trial of I-131-CLR1404 in Multiple Myeloma
GlobeNewswire - Wed Apr 15, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced the initiation of patient dosing in a proof-of-concept trial of I-131-CLR1404 in patients with relapsed or refractory multiple myeloma, an indication for which I-131-CLR1404 previously received orphan drug designation from the U.S. Food and Drug Administration.
CLRB: 3.13 (+0.02)
Cellectar Biosciences' (CLRB) CEO Simon Pedder on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 24, 7:18PM CDT
CLRB: 3.13 (+0.02)
Cellectar Biosciences reports FY'14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:24PM CDT
CLRB: 3.13 (+0.02)
Cellectar Biosciences Full-Year 2014 Financial Results and Recent Highlights
GlobeNewswire - Tue Mar 24, 3:15PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the year ended December 31, 2014.
CLRB: 3.13 (+0.02)
Cellectar Biosciences to Host Conference Call on March 24th to Discuss Fourth Quarter and Full Year 2014 Results and Provide Update on Development Progress
GlobeNewswire - Tue Mar 17, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss fourth quarter and full year 2014 financial results and provide an update on each of its development programs on Tuesday, March 24th at 5:00 PM ET.
CLRB: 3.13 (+0.02)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 3.13 (+0.02), IMMU: 4.09 (-0.02), ADXS: 23.34 (-0.27), CERU: 6.27 (+0.07), IMGN: 9.96 (-0.29), ARQL: 2.12 (unch), AMGN: 167.91 (-1.26), GSK: 46.59 (+0.28), BMY: 65.80 (-0.20), OMER: 24.32 (-0.35), MACK: 13.42 (-0.25), BLCM: 27.88 (-0.46), AZN: 71.79 (-1.34), AVEO: 1.92 (-0.08), NVS: 104.28 (-1.22), KPTI: 31.49 (-1.13), CELGZ: 2.76 (-0.12)
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 136.26 (-3.82), CLRB: 3.13 (+0.02), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Cellectar Biosciences to Present at the 17th Annual BIO CEO & Investor Conference 2015
GlobeNewswire - Fri Feb 06, 7:30AM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, today announced that Dr. Simon Pedder, president and CEO, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 09, 2015 at 08:30 am EST at the Waldorf Astoria in New York City.
CLRB: 3.13 (+0.02)
Peer-Reviewed Glioma Surgery Study With Cellectar Biosciences Fluorescence Cancer-Targeting Agents Chosen for the Cover of Neurosurgery
GlobeNewswire - Thu Jan 22, 7:30AM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced publication of the first peer-reviewed proof-of-principle study of a new class of fluorescent alkylphosphocholine analogs for fluorescence-guided glioma surgery in Neurosurgery, official journal of the Congress of Neurological Surgeons - the largest neurosurgical society in the world. This study is featured on the cover of the February 2015 issue, and demonstrates that the fluorescent cancer-selective CLR1501 and CLR1502 agents successfully provide visualization of glioma cancer cells with high fidelity, and suggest their practical and promising potential to optimize tumor surgery.
CLRB: 3.13 (+0.02)
Cellectar Biosciences to Present at the Biotech Showcase 2015 Conference
GlobeNewswire - Fri Jan 09, 7:30AM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced today that Dr. Simon Pedder, Chief Executive Officer, will be presenting at the Biotech Showcase(TM) 2015 Conference being held at the Parc 55 Wyndham in San Francisco, CA.
CLRB: 3.13 (+0.02)
Cellectar Biosciences receives US FDA's orphan drug designation for I-131-CLR1404 for multiple myeloma
M2 - Fri Dec 05, 4:16AM CST
Biopharmaceutical company Cellectar Biosciences (NasdaqCM:CLRB) reported on Thursday that it has received the US Food and Drug Administration's (FDA) orphan drug designation for I-131-CLR1404 for the treatment of multiple myeloma, an incurable cancer of plasma cells.
CLRB: 3.13 (+0.02)
Cellectar Biosciences Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma
GlobeNewswire - Thu Dec 04, 3:05PM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has granted Cellectar's request for orphan drug designation of I-131-CLR1404 for the treatment of multiple myeloma, an incurable cancer of plasma cells.
CLRB: 3.13 (+0.02)
Cellectar Biosciences hires Dr Cameron Szakacs as VP of Clinical Development
M2 - Wed Nov 26, 6:44AM CST
Cancer compound company Cellectar Biosciences (NasdaqCM:CLRB) disclosed on Tuesday the addition of Dr Cameron Szakacs, PhD as vice president of its clinical development.
CLRB: 3.13 (+0.02)
Cellectar Biosciences Names Cameron Szakacs, Ph.D. Vice President of Clinical Development
GlobeNewswire - Tue Nov 25, 7:31AM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), announced the appointment of Cameron Szakacs, Ph.D., as vice president of clinical development. Dr. Szakacs brings over 18 years of leadership and experience in the pharmaceutical industry, including expertise in the strategy, design and execution of global clinical programs in oncology and orphan indications.
CLRB: 3.13 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.83 (+0.03), CLRB: 3.13 (+0.02), MPX: 8.13 (-0.39), FATE: 5.91 (-0.24), TTPH: 40.03 (-0.67), PHMD: 2.05 (+0.09), BIND: 6.84 (-0.33), AXPW: 0.04 (unch), CANF: 2.17 (+0.02), SYN: 2.33 (+0.01), RNA: 18.65 (unch), CLIR: 5.54 (-0.02), VSCI: 0.35 (-0.02), OCRX: 3.89 (+0.08), GALE: 1.45 (+0.02), REI: 11.46 (-0.04), OGEN: 0.92 (unch), PTP: 76.52 (+0.17), FPRX: 24.20 (-0.26)
Cellectar Biosciences reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:15PM CST
CLRB: 3.13 (+0.02)
Cellectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Tue Nov 11, 3:05PM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the third quarter 2014.
CLRB: 3.13 (+0.02)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.13 (+0.02), CRIS: 2.96 (-0.01), IMMU: 4.09 (-0.02), PCYC: 256.59 (-0.51), ONCY: 0.75 (-0.05), PFE: 35.27 (-0.09), LLY: 71.58 (-0.82), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), JNJ: 101.08 (+0.62), SNTA: 2.69 (-0.28), NVS: 104.28 (-1.22), XLRN: 33.29 (-0.95), ARRY: 7.19 (-0.12), CELGZ: 2.76 (-0.12), EXEL: 3.08 (-0.02)
Cellectar Bio initiates Phase 1 study of I-131-CLR1404 for Orphan Drug indication
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 12:08PM CDT
CLRB: 3.13 (+0.02)
Cellectar Biosciences Initiates Proof-of-Concept Trial of I-131-CLR1404 in Multiple Myeloma
GlobeNewswire - Wed Apr 15, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced the initiation of patient dosing in a proof-of-concept trial of I-131-CLR1404 in patients with relapsed or refractory multiple myeloma, an indication for which I-131-CLR1404 previously received orphan drug designation from the U.S. Food and Drug Administration.
CLRB: 3.13 (+0.02)
Cellectar Biosciences' (CLRB) CEO Simon Pedder on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 24, 7:18PM CDT
CLRB: 3.13 (+0.02)
Cellectar Biosciences reports FY'14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:24PM CDT
CLRB: 3.13 (+0.02)
Cellectar Biosciences Full-Year 2014 Financial Results and Recent Highlights
GlobeNewswire - Tue Mar 24, 3:15PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the year ended December 31, 2014.
CLRB: 3.13 (+0.02)
Cellectar Biosciences to Host Conference Call on March 24th to Discuss Fourth Quarter and Full Year 2014 Results and Provide Update on Development Progress
GlobeNewswire - Tue Mar 17, 7:30AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss fourth quarter and full year 2014 financial results and provide an update on each of its development programs on Tuesday, March 24th at 5:00 PM ET.
CLRB: 3.13 (+0.02)
Esophageal Cancer Therapeutics Pipeline Review 2015 - 40 Companies & 57 Drug Profiles
M2 - Wed Mar 11, 7:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2mqnm8/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Advaxis, Inc. - Amgen Inc. - ArQule, Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Cerulean Pharma, Inc. - Daiichi Sankyo Company, Limited - Genmab A/S - GlaxoSmithKline plc - Glycotope GmbH - Hutchison MediPharma Limited - ImmunoFrontier, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Karyopharm Therapeutics, Inc. - Mebiopharm Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Omeros Corporation - Omnitura Therapeutics Inc. - Oncolys BioPharma Inc. - Ono Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/2m...eal_cancer
CLRB: 3.13 (+0.02), IMMU: 4.09 (-0.02), ADXS: 23.34 (-0.27), CERU: 6.27 (+0.07), IMGN: 9.96 (-0.29), ARQL: 2.12 (unch), AMGN: 167.91 (-1.26), GSK: 46.59 (+0.28), BMY: 65.80 (-0.20), OMER: 24.32 (-0.35), MACK: 13.42 (-0.25), BLCM: 27.88 (-0.46), AZN: 71.79 (-1.34), AVEO: 1.92 (-0.08), NVS: 104.28 (-1.22), KPTI: 31.49 (-1.13), CELGZ: 2.76 (-0.12)
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 136.26 (-3.82), CLRB: 3.13 (+0.02), BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), JUNO: 56.66 (-1.06), NVS: 104.28 (-1.22)
Cellectar Biosciences to Present at the 17th Annual BIO CEO & Investor Conference 2015
GlobeNewswire - Fri Feb 06, 7:30AM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, today announced that Dr. Simon Pedder, president and CEO, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 09, 2015 at 08:30 am EST at the Waldorf Astoria in New York City.
CLRB: 3.13 (+0.02)
Peer-Reviewed Glioma Surgery Study With Cellectar Biosciences Fluorescence Cancer-Targeting Agents Chosen for the Cover of Neurosurgery
GlobeNewswire - Thu Jan 22, 7:30AM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced publication of the first peer-reviewed proof-of-principle study of a new class of fluorescent alkylphosphocholine analogs for fluorescence-guided glioma surgery in Neurosurgery, official journal of the Congress of Neurological Surgeons - the largest neurosurgical society in the world. This study is featured on the cover of the February 2015 issue, and demonstrates that the fluorescent cancer-selective CLR1501 and CLR1502 agents successfully provide visualization of glioma cancer cells with high fidelity, and suggest their practical and promising potential to optimize tumor surgery.
CLRB: 3.13 (+0.02)
Cellectar Biosciences to Present at the Biotech Showcase 2015 Conference
GlobeNewswire - Fri Jan 09, 7:30AM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced today that Dr. Simon Pedder, Chief Executive Officer, will be presenting at the Biotech Showcase(TM) 2015 Conference being held at the Parc 55 Wyndham in San Francisco, CA.
CLRB: 3.13 (+0.02)
Cellectar Biosciences receives US FDA's orphan drug designation for I-131-CLR1404 for multiple myeloma
M2 - Fri Dec 05, 4:16AM CST
Biopharmaceutical company Cellectar Biosciences (NasdaqCM:CLRB) reported on Thursday that it has received the US Food and Drug Administration's (FDA) orphan drug designation for I-131-CLR1404 for the treatment of multiple myeloma, an incurable cancer of plasma cells.
CLRB: 3.13 (+0.02)
Cellectar Biosciences Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma
GlobeNewswire - Thu Dec 04, 3:05PM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has granted Cellectar's request for orphan drug designation of I-131-CLR1404 for the treatment of multiple myeloma, an incurable cancer of plasma cells.
CLRB: 3.13 (+0.02)
Cellectar Biosciences hires Dr Cameron Szakacs as VP of Clinical Development
M2 - Wed Nov 26, 6:44AM CST
Cancer compound company Cellectar Biosciences (NasdaqCM:CLRB) disclosed on Tuesday the addition of Dr Cameron Szakacs, PhD as vice president of its clinical development.
CLRB: 3.13 (+0.02)
Cellectar Biosciences Names Cameron Szakacs, Ph.D. Vice President of Clinical Development
GlobeNewswire - Tue Nov 25, 7:31AM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), announced the appointment of Cameron Szakacs, Ph.D., as vice president of clinical development. Dr. Szakacs brings over 18 years of leadership and experience in the pharmaceutical industry, including expertise in the strategy, design and execution of global clinical programs in oncology and orphan indications.
CLRB: 3.13 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.83 (+0.03), CLRB: 3.13 (+0.02), MPX: 8.13 (-0.39), FATE: 5.91 (-0.24), TTPH: 40.03 (-0.67), PHMD: 2.05 (+0.09), BIND: 6.84 (-0.33), AXPW: 0.04 (unch), CANF: 2.17 (+0.02), SYN: 2.33 (+0.01), RNA: 18.65 (unch), CLIR: 5.54 (-0.02), VSCI: 0.35 (-0.02), OCRX: 3.89 (+0.08), GALE: 1.45 (+0.02), REI: 11.46 (-0.04), OGEN: 0.92 (unch), PTP: 76.52 (+0.17), FPRX: 24.20 (-0.26)
Cellectar Biosciences reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:15PM CST
CLRB: 3.13 (+0.02)
Cellectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Tue Nov 11, 3:05PM CST
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the third quarter 2014.
CLRB: 3.13 (+0.02)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 3.13 (+0.02), CRIS: 2.96 (-0.01), IMMU: 4.09 (-0.02), PCYC: 256.59 (-0.51), ONCY: 0.75 (-0.05), PFE: 35.27 (-0.09), LLY: 71.58 (-0.82), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), JNJ: 101.08 (+0.62), SNTA: 2.69 (-0.28), NVS: 104.28 (-1.22), XLRN: 33.29 (-0.95), ARRY: 7.19 (-0.12), CELGZ: 2.76 (-0.12), EXEL: 3.08 (-0.02)
